COCP - Cocrystal Pharma, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Cocrystal Pharma, Inc.

1860 Montreal Road
Tucker, GA 30084
United States

Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Dr. Gary L. WilcoxCo-Founder, Vice Chairman & Interim CEON/AN/A1947
Dr. Sam LeeCo-Founder & PresN/AN/A1960
Mr. James J. Martin CPA, CPA, MBACFO & Sec.199.56kN/A1967
Dr. Roger D. KornbergCo-Founder, Chairman of Scientific Advisory Board & Chief ScientistN/AN/A1947
Dr. Luz PascualVP of Clinical Devel.N/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cocrystal Pharma, Inc., a clinical stage biotechnology company, engages in discovering and developing various novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. It employs structure-based technologies to create antiviral drugs. The company's products include CC-31244, a Phase IIa ready broad-spectrum novel non-nucleoside replication inhibitor for the treatment of hepatitis C virus; and CC-42344, a novel PB2 inhibitor that is in preclinical development trials for the treatment of influenza. It also has a pipeline of products that are in early preclinical programs. The company has collaborations with Emory University; University of Pittsburgh; and NIH. Cocrystal Pharma, Inc. was founded in 2007 and is headquartered in Tucker, Georgia.

Corporate Governance

Cocrystal Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.